NO20076404L - Humaniserte anti-CD40 antistoffer og deres anvendelsesmetoder - Google Patents
Humaniserte anti-CD40 antistoffer og deres anvendelsesmetoderInfo
- Publication number
- NO20076404L NO20076404L NO20076404A NO20076404A NO20076404L NO 20076404 L NO20076404 L NO 20076404L NO 20076404 A NO20076404 A NO 20076404A NO 20076404 A NO20076404 A NO 20076404A NO 20076404 L NO20076404 L NO 20076404L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- methods
- humanized anti
- antigen
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Sammendrag Tilveiebrakt er humaniserte anti-CD40-antistoffer og antigen-bindende fragmenter og fremgangsmåter for behandling av sykdom kjennetegnet ved ekspresjon av CD40antigen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68485305P | 2005-05-26 | 2005-05-26 | |
PCT/US2006/020688 WO2006128103A2 (en) | 2005-05-26 | 2006-05-26 | Humanized anti-cd40 antibodies and their methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20076404L true NO20076404L (no) | 2008-02-13 |
NO341793B1 NO341793B1 (no) | 2018-01-22 |
Family
ID=37452957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20076404A NO341793B1 (no) | 2005-05-26 | 2007-12-12 | Humaniserte anti-CD40 antistoffer eller antigenbindende fragment, farmasøytisk sammensetning, isolert polynukleotid og kit |
Country Status (19)
Country | Link |
---|---|
US (4) | US8303955B2 (no) |
EP (1) | EP1885399B1 (no) |
JP (1) | JP5027804B2 (no) |
KR (1) | KR100991010B1 (no) |
CN (1) | CN101237882B (no) |
AT (1) | ATE485057T1 (no) |
AU (1) | AU2006249305B2 (no) |
BR (1) | BRPI0610470A2 (no) |
CA (1) | CA2609269C (no) |
CR (1) | CR9562A (no) |
DE (1) | DE602006017690D1 (no) |
EC (1) | ECSP078026A (no) |
ES (1) | ES2354865T3 (no) |
IL (1) | IL187594A0 (no) |
MA (1) | MA29595B1 (no) |
NO (1) | NO341793B1 (no) |
PL (1) | PL1885399T3 (no) |
RU (1) | RU2407544C2 (no) |
WO (1) | WO2006128103A2 (no) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
ATE485057T1 (de) * | 2005-05-26 | 2010-11-15 | Seattle Genetics Inc | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung |
EP1968636A4 (en) * | 2005-12-09 | 2010-06-02 | Seattle Genetics Inc | METHOD OF USE OF CD40 BONDING AGENTS |
WO2008091954A2 (en) * | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
US9068230B2 (en) | 2007-11-07 | 2015-06-30 | Genentech, Inc. | Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
FR2942799B1 (fr) * | 2009-03-06 | 2011-02-25 | Lfb Biotechnologies | Anticorps monoclonal anti-rhesus d |
AU2010222942B2 (en) | 2009-03-10 | 2013-01-10 | Baylor Research Institute | Anti-CD40 antibodies and uses thereof |
BRPI1009194A2 (pt) | 2009-03-10 | 2016-11-01 | Baylor Res Inst | vacinas direcionadas à célula apresentadora de antígeno |
JP5986382B2 (ja) | 2009-03-10 | 2016-09-06 | ベイラー リサーチ インスティテュートBaylor Research Institute | 抗原提示細胞ターゲティング癌ワクチン |
AU2010236168B2 (en) | 2009-04-18 | 2015-08-13 | Genentech, Inc. | Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
US20130052194A1 (en) | 2009-12-16 | 2013-02-28 | The Trustees Of The University Of Pennsylvania | Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same |
EA031872B1 (ru) | 2010-03-31 | 2019-03-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Гуманизированное антитело к cd40, его применение, фармацевтическая композиция, содержащая это антитело, и выделенный полинуклеотид, кодирующий его |
FI3556774T3 (fi) | 2011-03-11 | 2024-03-15 | Beth Israel Deaconess Medical Ct Inc | Anti-cd40-vasta-aineita ja niiden käyttötapoja |
EP2688592A4 (en) | 2011-03-25 | 2015-07-22 | Baylor Res Inst | COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST HEPATITIS C VIRUS |
KR20190122889A (ko) | 2011-04-29 | 2019-10-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
BR112014008804A2 (pt) * | 2011-10-11 | 2017-06-13 | Medimmune Llc | suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
CN109265552A (zh) | 2012-10-30 | 2019-01-25 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
EP3094652B1 (en) | 2014-01-13 | 2021-09-29 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
KR102632731B1 (ko) | 2014-04-30 | 2024-02-01 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Cd269에 대한 인간화 항체 |
DK3180087T3 (da) | 2014-08-12 | 2019-05-13 | Alligator Bioscience Ab | Kombinationsterapier med anti cd40-antistoffer |
CN107073118B (zh) | 2014-10-29 | 2022-03-01 | 西雅图基因公司 | 非岩藻糖基化抗cd40抗体的剂量和给药 |
AU2015350190B2 (en) * | 2014-11-18 | 2021-08-05 | Janssen Pharmaceutica Nv | CD47 antibodies, methods, and uses |
JP6971850B2 (ja) | 2015-04-13 | 2021-11-24 | ファイヴ プライム セラピューティクス インク | がんの併用療法 |
HUE063528T2 (hu) * | 2015-09-01 | 2024-01-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére |
SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
MY196646A (en) * | 2015-09-30 | 2023-04-27 | Janssen Biotech Inc | Agonistic Antibodies Specifically Binding Human CD40 And Methods of use |
WO2017062653A2 (en) * | 2015-10-08 | 2017-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Blockade of tim-1 for treating graft-versus-host disease |
LT3370768T (lt) | 2015-11-03 | 2022-05-25 | Janssen Biotech, Inc. | Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas |
EA039944B1 (ru) * | 2016-01-27 | 2022-03-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Применение антител к cd40 для лечения волчаночного нефрита |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
SG11201900746RA (en) | 2016-08-12 | 2019-02-27 | Janssen Biotech Inc | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
JP7009448B2 (ja) | 2016-08-12 | 2022-02-10 | ヤンセン バイオテツク,インコーポレーテツド | 強化されたアゴニスト活性を有する、Fcが遺伝子操作を受けた抗TNFRスーパーファミリーメンバー抗体及びその使用方法 |
CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
EP3525813B1 (en) * | 2016-10-11 | 2024-04-17 | Razi Holdings, Inc. | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop |
CN109890416B (zh) * | 2016-11-07 | 2024-04-30 | 西雅图基因公司 | 工程化半胱氨酸帽的分布 |
WO2018088850A2 (ko) * | 2016-11-11 | 2018-05-17 | 다이노나(주) | Cd40에 특이적으로 결합하는 항체 및 그의 용도 |
JP7304287B2 (ja) | 2016-12-22 | 2023-07-06 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療 |
BR112019017753B1 (pt) * | 2017-04-04 | 2024-04-30 | F. Hoffmann-La Roche Ag | Molécula biespecífica de ligação ao antígeno, composição farmacêutica e uso da molécula biespecífica de ligação ao antígeno |
US11525005B2 (en) | 2017-06-01 | 2022-12-13 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
BR112020006443A2 (pt) | 2017-11-01 | 2020-09-29 | F. Hoffmann-La Roche Ag | anticorpos biespecíficos, ácido nucleico isolado, vetor ou célula hospedeira, método para produzir um anticorpo biespecífico e para tratar um indivíduo, composição farmacêutica e uso do anticorpo |
EP3732198A1 (en) * | 2017-12-27 | 2020-11-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
MA52889A (fr) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V Inc | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires |
JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗tigit抗体 |
SG11202102477QA (en) * | 2018-10-01 | 2021-04-29 | Hoffmann La Roche | Bispecific antigen binding molecules comprising anti-fap clone 212 |
EP3861025A1 (en) * | 2018-10-01 | 2021-08-11 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules with trivalent binding to cd40 |
EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
MX2021006360A (es) | 2018-11-30 | 2021-08-11 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica de anticuerpo cd40 y uso de la misma. |
KR20210099027A (ko) | 2018-11-30 | 2021-08-11 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도 |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
WO2020253722A1 (en) * | 2019-06-17 | 2020-12-24 | Eucure (Beijing) Biopharma Co., Ltd | Anti-cd40 antibodies and uses thereof |
EP4027998A1 (en) | 2019-09-09 | 2022-07-20 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
TW202206100A (zh) | 2020-04-27 | 2022-02-16 | 美商西健公司 | 癌症之治療 |
CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
EP4221751A1 (en) | 2020-09-30 | 2023-08-09 | Seagen Inc. | Uveal melanoma treatment using sea-cd40 |
AU2021376218A1 (en) | 2020-11-08 | 2023-06-15 | Seagen Inc. | Combination Therapy |
US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
TW202314247A (zh) | 2021-05-25 | 2023-04-01 | 美商思進公司 | 量化抗cd40抗體之方法 |
CN115403670A (zh) | 2021-05-26 | 2022-11-29 | 安徽瀚海博兴生物技术有限公司 | 抗cd40抗体及其用途 |
CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023010080A1 (en) | 2021-07-30 | 2023-02-02 | Seagen Inc. | Treatment for cancer |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182368A (en) * | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
IL84285A (en) * | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
US5985847A (en) * | 1993-08-26 | 1999-11-16 | The Regents Of The University Of California | Devices for administration of naked polynucleotides which encode biologically active peptides |
US5597569A (en) * | 1993-10-25 | 1997-01-28 | Bristol-Myers Squibb Company | Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica |
DE69433820T2 (de) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
EP0966480A2 (en) | 1997-01-30 | 1999-12-29 | The University Of Virginia Patent Foundation | Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
DE69941165D1 (de) * | 1998-05-23 | 2009-09-03 | Univ Leiden Medical Ct | CD40 bindende Moleküle und CTL Peptide zur Behandlung von Tumoren |
US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
JP2003527861A (ja) | 2000-03-16 | 2003-09-24 | ジェネンテック・インコーポレーテッド | 増強した抗血液凝固能を持つ抗組織因子抗体 |
CA2430249A1 (en) * | 2000-12-14 | 2002-06-20 | Genentech, Inc. | Bacterial host strains |
DE602004027888D1 (de) * | 2003-02-20 | 2010-08-12 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihr |
WO2005056759A2 (en) * | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
US20060003412A1 (en) * | 2003-12-08 | 2006-01-05 | Xencor, Inc. | Protein engineering with analogous contact environments |
US7329737B2 (en) * | 2004-08-03 | 2008-02-12 | Dyax Corp. | Antibodies that bind hK-1 |
ATE460672T1 (de) * | 2005-05-20 | 2010-03-15 | Genentech Inc | Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit |
ATE485057T1 (de) * | 2005-05-26 | 2010-11-15 | Seattle Genetics Inc | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung |
-
2006
- 2006-05-26 AT AT06771453T patent/ATE485057T1/de not_active IP Right Cessation
- 2006-05-26 US US11/913,305 patent/US8303955B2/en active Active
- 2006-05-26 WO PCT/US2006/020688 patent/WO2006128103A2/en active Application Filing
- 2006-05-26 BR BRPI0610470-3A patent/BRPI0610470A2/pt not_active IP Right Cessation
- 2006-05-26 EP EP06771453A patent/EP1885399B1/en active Active
- 2006-05-26 KR KR1020077030332A patent/KR100991010B1/ko active IP Right Grant
- 2006-05-26 ES ES06771453T patent/ES2354865T3/es active Active
- 2006-05-26 PL PL06771453T patent/PL1885399T3/pl unknown
- 2006-05-26 RU RU2007148932/10A patent/RU2407544C2/ru active
- 2006-05-26 CN CN2006800271172A patent/CN101237882B/zh active Active
- 2006-05-26 JP JP2008513805A patent/JP5027804B2/ja active Active
- 2006-05-26 CA CA2609269A patent/CA2609269C/en active Active
- 2006-05-26 AU AU2006249305A patent/AU2006249305B2/en active Active
- 2006-05-26 DE DE602006017690T patent/DE602006017690D1/de active Active
-
2007
- 2007-11-22 IL IL187594A patent/IL187594A0/en unknown
- 2007-12-06 CR CR9562A patent/CR9562A/es not_active Application Discontinuation
- 2007-12-11 MA MA30474A patent/MA29595B1/fr unknown
- 2007-12-12 NO NO20076404A patent/NO341793B1/no unknown
- 2007-12-17 EC EC2007008026A patent/ECSP078026A/es unknown
-
2012
- 2012-09-19 US US13/622,517 patent/US8492531B2/en active Active
-
2013
- 2013-06-25 US US13/926,817 patent/US20130315900A1/en not_active Abandoned
-
2014
- 2014-03-10 US US14/202,923 patent/US20140193405A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1885399A4 (en) | 2009-04-22 |
WO2006128103A3 (en) | 2007-01-18 |
WO2006128103A2 (en) | 2006-11-30 |
KR100991010B1 (ko) | 2010-10-29 |
CN101237882A (zh) | 2008-08-06 |
KR20080030958A (ko) | 2008-04-07 |
EP1885399A2 (en) | 2008-02-13 |
US8303955B2 (en) | 2012-11-06 |
US20140193405A1 (en) | 2014-07-10 |
MA29595B1 (fr) | 2008-07-01 |
US20090181015A1 (en) | 2009-07-16 |
DE602006017690D1 (de) | 2010-12-02 |
EP1885399B1 (en) | 2010-10-20 |
US20130023047A1 (en) | 2013-01-24 |
ES2354865T3 (es) | 2011-03-18 |
AU2006249305A1 (en) | 2006-11-30 |
IL187594A0 (en) | 2008-03-20 |
RU2407544C2 (ru) | 2010-12-27 |
NO341793B1 (no) | 2018-01-22 |
CA2609269C (en) | 2014-08-05 |
RU2007148932A (ru) | 2009-07-10 |
CA2609269A1 (en) | 2006-11-30 |
JP5027804B2 (ja) | 2012-09-19 |
CR9562A (es) | 2008-03-06 |
BRPI0610470A2 (pt) | 2010-06-22 |
ATE485057T1 (de) | 2010-11-15 |
JP2008541733A (ja) | 2008-11-27 |
ECSP078026A (es) | 2008-03-26 |
AU2006249305B2 (en) | 2012-10-18 |
PL1885399T3 (pl) | 2011-04-29 |
US20130315900A1 (en) | 2013-11-28 |
US8492531B2 (en) | 2013-07-23 |
CN101237882B (zh) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20076404L (no) | Humaniserte anti-CD40 antistoffer og deres anvendelsesmetoder | |
CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
LTPA2017040I1 (lt) | Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui | |
NO20084650L (no) | Modifiserte humaniserte anti-interleukin-18 antistoffer | |
EA200702064A1 (ru) | Новое анти-plgf антитело | |
HRP20171337T1 (hr) | Monoklonska antitijela protiv klaudina-18 za liječenje karcinoma | |
DK1758610T3 (da) | Fremgangsmåder til behandling af cancer ved hjælp af IL-21 og monoklonal antistofterapi | |
AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
GT200900002A (es) | Anticuerpo antagonista para el tratamiento del cancer | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
IL188591A0 (en) | Methods of treating autoimmune disease using humanized anti-cd16a antibodies | |
NO20082167L (no) | Anti-Myostatin-antistoffer | |
NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
DK1960434T3 (da) | Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1 | |
MX2009009636A (es) | Metodos para tratar enfermedades oftalmicas. | |
EP1811026A4 (en) | ANIMAL IMMUNIZATION METHOD, PREPARATION FOR IMMUNIZATION, METHOD FOR PRODUCING ANTIBODY, METHOD FOR PRODUCING HYBRIDOMA, AND METHOD FOR PRODUCING MONOCLONAL ANTIBODY | |
UA112521C2 (uk) | Антитіло проти gdf8 людини |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GENENTECH INC., US |